at physiologic pH. Sir Rudolph thought that a combined therapy, which most of us have used over the years on the most severely ill patients, would allow BAL to get into the cell and literally take out copper and allow penicillamineas he put itto stand on guard extracellularly, intravascularly and, taking copper from albumin or other compound which had loosely-bound copper, promote excretion of copper into urine. I suspect that the reason for Dr Schneider's success with cysteamine, and his lack of success with penicillamine, is the same as that pointed out 16 years ago by Sir Rudolph: in general charged molecules do not cross intracellular barriers, whereas uncharged molecules are much more likely to do so.
In fact, one might wonder whether BAL might not be effective in the treatment of cystinosis for the same reason. Dr Schneider: BAL has been tried.
Dr J Czekalowski (Leeds): Has histology been carried out on the kidneys in cystinosis ? Dr Schneider: I have not done so personally, but many people have. Dr Czekalowski: Have crystals been seen in the tubular cells and glomeruli ? Dr Schneider: Yes, crystals have been seen in the cell. Unfortunately, the histology is extremely difficult to do because by the time these children are diagnosed they already have severe kidney damage. Consequently, the kidneys that are studied are scarred and fibrotic. But it appears that crystals are seen in some of the tubular cells and the glomeruli. Dr Czekalowski: It was mentioned that kidney transplant may be of help later in these childrenbut for how long? Dr Schneider: I do not advocate this as a cure because it is clearly not a cure. But we now know of several patients alive 10 years after transplantation. These children do as well with kidney transplants as any children domeaning that some do very well, some do very poorly and most do so-so.
Dr Stephens: Does Dr Schneider know what the difference is between the two types of intracellular crystals that he demonstratedthe rectangular birefringent ones and the typical hexagonal cystine crystals ? Dr Schneider: It might simply relate to the angle from which they are being observed.
SUMMING UP
Dr J C Crawhall (Montreal): I will take this opportunity to try to sum up. I wanted to summarize because I did not know what Dr Stephens and Mr Purkiss would say in their papers. I can now tie in their comments with my own experience.
There are two parts to the summary: the first is the practical one of the management of cystinuria. Cystinuria is a condition which leads to considerable distress from renal colic, ureteric obstruction and recurrent surgery. Penicillamine is of value to those suffering these disorders. We want to try to establish whether the complications are dose-related. On the premise that they may be, we want to be able to use the minimum penicillamine dosage compatible with prevention of stone formation.
Secondly, the reason why we started to talk a little about cystinosis is to enlarge our ideas on thiol drugs and their mechanism of action. As Dr Schneider showed, there are a large number of possible substances of this sort. There may be a number of factors of importance: for instance, molecular size, charge or optical configurationwhich has not been mentioned, One reason why penicillamine may have a limited effect in this condition is that the active transport mechanisms of cell membranes are geared to L-amino acids, not D-amjno acids. Thus, there may be a specific mechanism for keeping the D-amino acids out.
Cysteamine carries quite a heavy charge, yet it seems able to get in to cells. The other compound, dithiothreitol, which carries no charge, is also extremely effective in this respect. It seems that there is probably a whole area of fundamental study that could be carried out, and about which we will probably hear more during the course of this symposium.
